We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We’re looking forward to the upcoming 50th Annual Meeting of the EBMT which is taking place in Glasgow, between 14 – 17 April 2024. Promising attendees an opportunity to explore the latest technologies, treatments and products in the field of oncology, we are excited to provide independent, expert video coverage of key data. You can […]
The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this […]
This year, in partnership with ESMO23, the European Oncology Nurses Society (EONS) held its annual meeting – EONS16. The theme of EONS16 was ‘Cancer nursing: Building on innovation and building back better’. To address this, the event covered a wide range of topics including health promotion, prevention and screening; supportive and person-centred care; symptom management; […]
We’re looking forward to the upcoming ASH Annual Meeting & Exposition 2023 which is taking place in San Diego between 9 – 12 December.
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros […]
As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about developing a successful career in medial oncology. For those that were unable to attend the […]
Significant advancements in breast cancer research emerged from ESMO 2023. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) breast […]
To further understand the potential of durvalumab (DUR) plus tremelimumab (TRE) in the treatment of soft tissue sarcoma (STS) we spoke with Prof. Viktor Grünwald (University Hospital Essen, Germany). At ESMO 2023, Prof. Grünwald presented results from the MEDISARC trial (NCT03317457), a study designed to test whether DUR + TRE improved overall survival compared to […]
Get the latest clinical insights from touchONCOLOGY